Search Results

As life sciences companies feel the burn of the current economy, one Bay Area biotech, CODA Biotherapeutics, quietly shut its doors.

CODA Biotherapeutics, Inc. today announced the appointment of Susan Catalano, Ph.D., as chief scientific officer.

CODA Biotherapeutics, Inc. (“CODA”), today announced the presentation of preclinical data suggesting that the Company’s chemogenetic gene therapy platform can control focal seizures in vivo.

Susan Catalano, Ph.D., joined CODA Biotherapeutics as chief scientific officer after 14 years as CEO of Cognition Therapeutics, the company she founded in 2007 and took public in 2021.

CODA Biotherapeutics, Inc. today announced it has closed on $28 million in financing led by Pacira BioSciences, Inc.

Data presented at 2022 Epilepsy Foundation Pipeline Conference provide additional in vivo proof of concept for CODA’s engineered receptors and activator drugs in controlling seizures.

CODA Biotherapeutics, Inc. today announced that preclinical data from the Company’s focal epilepsy program will be featured as a poster presentation at the American Society of Gene & Cell Therapy 25th Annual Meeting being held virtually and in person, May 16-19, 2022, in Washington, D.C.

Strategic partnership supports CODA’s efforts to develop gene-therapy mediated treatments and cures for trigeminal neuralgia and related neuropathic pain [20-May-2020] SOUTH SAN FRANCISCO, Calif. , May 20, 2020 /PRNewswire/ -- CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, today annou

As the American Society of Gene & Cell Therapy’s 25th Annual Meeting wraps up, a host of life science companies touted their research and products. BioSpace looks at some of them.

CODA Biotherapeutics, Inc., a preclinical-stage biopharmaceutical company developing a gene therapy-mediated chemogenetic platform, today announced it has completed the acquisition of Attenua, Inc.